



INFORMATION ABOUT THE UNIVERSITY OF OXFORD VACCINE FOR COVID-19

The University of Oxford vaccine is one of the most progressed vaccines in development globally for Coronavirus (COVID-19). If it is proven to be safe and effective and is approved for use, it will be available in Australia from early 2021, as part of the Australian Government's COVID-19 Vaccine and Treatment Strategy.

In Australia, the vaccine would be manufactured by Australian-headquartered multinational biopharmaceutical company CSL in partnership with the developer, international pharmaceutical company AstraZeneca. The Oxford vaccine is one of nine vaccines supported by the Coalition for Epidemic Preparedness Innovations (CEPI), a global partnership to accelerate vaccine development.

Status	Type	Developer	Likely doses
Phase 3 clinical trials	Viral vector vaccine	AstraZeneca	Two



Testing process

All vaccines must pass different stages of research trials to prove they are safe and effective.

The CSIRO partnered with the CEPI to test the vaccine in pre-clinical (animal) trials in Australia.

The Oxford vaccine has completed combined Phase 1 and 2 clinical trials, where it was tested in a small number of volunteers to show that it is safe. Trial results showed a strong antibody and T-cell response in participants.

Larger combined Phase 2 and 3 clinical trials are now underway in the United Kingdom, United States, Brazil and South Africa.



Doses for Australia

Before the Oxford COVID-19 vaccine is approved for use in Australia it must pass the Therapeutic Goods Administration's (TGA) rigorous assessment and approval processes. This includes assessment of its safety, quality and effectiveness. The TGA is actively monitoring COVID-19 vaccine development that is occurring both in Australia and around the world. In October 2020, the TGA granted a provisional determination to AstraZeneca for this vaccine candidate. This means that it is now eligible to apply for provisional registration on the Australian Register of Therapeutic Goods. If the Oxford vaccine is successful:

- Australia has secured 53.8 million doses of this vaccine
- 3.8 million doses will be delivered to Australia in early 2021
- 50 million doses will be manufactured in Australia in monthly batches. CSL will manufacture these doses on behalf of AstraZeneca.